OnKure Therapeutics, Inc. (OKUR) Income Statement
OKUR 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsOKUR revenue and net income
OKUR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
OKUR quarterly EPS vs estimates
OnKure Therapeutics beat the analyst EPS estimate in 6 of the last 8 quarters. Next report: November 5, 2026 (estimate $-0.35).
OKUR income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | $830,000 | $662,000 | $560,000 | $529,000 | $50,000 | $37,000 |
| Gross profit | −$830,000 | −$662,000 | −$560,000 | −$529,000 | −$50,000 | −$37,000 |
| Research & development | $48.3M | $43.8M | $32.1M | $25.9M | $28.1M | $15.9M |
| Sales, general & admin | $14.7M | $10.6M | $4.8M | $3.9M | — | — |
| Total operating expenses | $62.1M | $54.4M | $36.9M | $29.8M | $39.8M | $19.5M |
| Operating income | −$63.0M | −$54.4M | −$36.9M | −$29.8M | −$39.8M | −$19.6M |
| Interest income | $3.4M | $2.0M | $1.6M | $254,000 | — | — |
| Interest expense | $8,000 | $300,000 | $0 | — | — | — |
| Income before taxes | −$59.5M | −$52.7M | −$35.3M | −$29.5M | −$39.8M | −$19.5M |
| Net income | −$59.5M | −$52.7M | −$35.3M | −$29.5M | −$39.8M | −$19.5M |
| EBITDA | −$58.7M | −$51.7M | −$34.8M | −$29.1M | −$39.7M | −$19.4M |
| EPS (diluted) | −$4.41 | −$6.36 | −$25.22 | −$21.21 | −$16.84 | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of revenue | — | $203,000 | $202,000 | — | $212,000 | $212,000 | $419,000 | $12,000 | $12,000 | $151,000 | $291,000 | $43,000 |
| Gross profit | — | −$203,000 | −$202,000 | — | −$212,000 | −$212,000 | −$419,000 | −$12,000 | −$12,000 | −$151,000 | −$291,000 | −$43,000 |
| Research & development | $12.6M | $11.7M | $10.7M | $11.9M | $12.6M | $13.0M | $37.4M | $892,000 | $10.8M | $8.6M | $6.9M | $13.6M |
| Sales, general & admin | $4.3M | $3.9M | $3.4M | $3.6M | $3.7M | $4.0M | $3.6M | $3.8M | $3.6M | $1.3M | $14.2M | $7.3M |
| Total operating expenses | $16.9M | $15.4M | $14.1M | $15.5M | $16.3M | $17.0M | $33.8M | $4.7M | $14.3M | $9.8M | −$21.1M | $20.7M |
| Operating income | −$16.9M | −$15.6M | −$14.1M | −$15.5M | −$16.3M | −$17.0M | −$33.8M | −$4.7M | −$14.3M | −$9.8M | $21.1M | −$20.7M |
| Interest income | $1.6M | $458,000 | $628,000 | $804,000 | $934,000 | $1.1M | — | $174,000 | $230,000 | $295,000 | — | — |
| Interest expense | — | — | $6,000 | $2,000 | $0 | — | — | $218,000 | $26,000 | — | — | — |
| Income before taxes | −$15.3M | −$15.2M | −$13.5M | −$14.7M | −$15.4M | −$15.9M | −$35.2M | −$3.7M | −$14.1M | −$9.5M | $18.5M | −$19.2M |
| Net income | −$15.3M | −$15.2M | −$13.5M | −$14.7M | −$15.4M | −$15.9M | −$35.2M | −$3.7M | −$14.1M | −$9.5M | $18.5M | −$19.2M |
| EBITDA | −$15.2M | −$15.0M | −$13.3M | −$14.5M | −$15.2M | −$15.7M | −$31.2M | −$3.7M | −$14.0M | −$9.4M | $19.0M | −$19.2M |
| EPS (diluted) | −$0.31 | −$1.11 | −$0.99 | −$1.09 | −$1.14 | −$1.19 | −$1.37 | −$0.86 | −$1.60 | −$2.52 | −$7.05 | −$5.68 |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in OKUR's financial statements (latest annual report filed March 12, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
OKUR financial results
OnKure Therapeutics reported no revenue in fiscal year 2025 (ended December 31, 2025). It had a net loss of $59.5 million. Diluted earnings per share came to −$4.41.
See the OKUR stock overview for the latest quote and news, or the OKUR chart for price history and technical indicators.
OKUR income statement FAQ
Does OnKure Therapeutics have revenue?
OnKure Therapeutics reported no revenue for fiscal year 2025, which ended on December 31, 2025.
Is OnKure Therapeutics profitable?
No. OnKure Therapeutics reported a net loss of $59.5 million in fiscal 2025.
How much does OnKure Therapeutics spend on research and development?
OnKure Therapeutics spent $48.3 million on research and development in fiscal 2025.
What are OnKure Therapeutics's earnings per share?
OnKure Therapeutics earned $-4.41 per diluted share in fiscal 2025, compared with $-6.36 a year earlier.
When will OnKure Therapeutics report its next earnings?
OnKure Therapeutics is expected to report results for the quarter ending September 30, 2026 on November 5, 2026.
When does OnKure Therapeutics's fiscal year end?
OnKure Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 12, 2026.